FDL176 ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	3

299. 嚢胞性線維症

---

臨床試験数 : 1,696 /  薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03756922 (ClinicalTrials.gov)	November 27, 2018	27/11/2018	A DDI Study of FDL169 and FDL176 in Healthy Subjects	A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation	Cystic Fibrosis	Drug: FDL169;Drug: FDL176	Flatley Discovery Lab LLC	NULL	Suspended	18 Years	55 Years	All	78	Phase 1/Phase 2	United Kingdom
2	NCT03516331 (ClinicalTrials.gov)	March 7, 2018	24/4/2018	A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects	A Phase 1, Open Label, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects	Cystic Fibrosis	Drug: FDL176 & FDL169 coadministration	Flatley Discovery Lab LLC	NULL	Completed	18 Years	55 Years	All	16	Phase 1	United Kingdom
3	NCT03173573 (ClinicalTrials.gov)	June 27, 2017	30/5/2017	A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants	A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants	Cystic Fibrosis	Drug: FDL176;Drug: Placebo	Flatley Discovery Lab LLC	NULL	Completed	18 Years	55 Years	All	109	Phase 1	Australia